Pulmagen develops novel and proprietary drugs for chronic respiratory diseases including COPD and asthma. These therapies aim to deliver both improved bronchodilator symptomatic relief and treat the underlying inflammatory disease process.
Pulmagen intends to progress its programs through Phase II proof-of-concept clinical trials and identify strategic partners for later stage clinical development.
The company has partnered respiratory drug development programs with AstraZeneca, Chiesi, Dr. Reddy's and Teijin.
Dr. Christopher Ashton
Chief Executive Officer
The Coach House